How MBA was paid
$4.8M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Other | Total |
|---|---|---|---|---|---|---|
| Shankar Musunuri, Ph.D., MBAChief Executive Officer, Chairman and Co-Founder | $757,900 | $500,214 | $2,194,445 | $1,385,871 | $3,392 | $4,841,822 |
| Ramesh Ramachandran, CPA, MBA, CMAChief Accounting Officer | $360,500 | $137,927 | $420,455 | $266,708 | $6,498 | $1,192,089 |
| Arun Upadhyay, Ph.D.Chief Scientific Officer | $480,146 | $209,601 | $877,778 | $554,500 | $14,004 | $2,136,069 |
| Huma Qamar, M.D., MPH, CMIChief Medical Officer | $448,050 | $190,130 | $1,375,478 | $868,975 | $5,847 | $2,888,481 |
What changed and why
- $4.8MShankar Musunuri received total compensation of $4,841,822 in 2025, an increase from $1,941,539 in 2024.
- 50%The long-term incentive mix for 2025 consisted of 50% stock options and 50% performance stock units.
- $758KDr. Musunuri's annual base salary remained flat at $757,900 for 2025.
- Performance stock units are earned based on TSR growth relative to the Nasdaq Biotechnology Index.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.